ArticleThe oncologist2025

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.

Apostolia M Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.